Article Text

PDF
AB0688 Effect of treatment with non-steroidal anti-inflammatory drugs on disease activity in patients with early axial spondyloarthritis base on data from 2 years follow up of corsar cohort
  1. D Rumiantceva,
  2. T Dubinina,
  3. O Rumyantseva,
  4. A Demina,
  5. E Agafonova,
  6. S Erdes,
  7. S Krasnenko
  1. Laboratory of spondyloarthritis, Nasonova Research Institute of Rheumatology, Moscow, Russia, Moscow, Russian Federation

Abstract

Background Currently non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line drugs for treatment of axial spondyloarthritis (axSpA) and much discussed question of influence frequency of intake NSAIDs on axSpA disease activity.

Objectives To compare the frequency of intake NSAIDs with early axSpA disease activity.

Methods The research included 65 patients (pts) with axSpA (criteria ASAS 2009) with disease duration <5 years and age at onset <45 years. Pts at least 2 years follow up, 32 (49,2%) males, pts mean age was 28,5 (5,8) y., average disease duration - 24,1 (15,4) mo, 60 (92,3%) pts were HLA-B27 positive. At baseline all pts were NSAID-naïve, DMARD-naïve, anti-TNF-naïve. For 2 years pts taking NSAIDs at therapeutic doses. The dosages of NSAIDs accounted by the ASAS NSAID index. 1 year after baseline – 9 (13,8%) pts started treatment with anti – TNF because of high activity of the disease and absence of effect from 2 NSAIDs. 2 years after baseline number of pts with anti-TNF equal - 15 (23,0%).

Results Compared with baseline characteristic after 2 years have significantly reduced disease activity and increased the number of ASAS partial remission (PR) in patients with axSpA (Table 1).

Table 1.

Outcome parameters at baseline and after 2 years of NSAID treatment

There were no statistical differences between the frequency of NSAIDs intake and early axSpA disease activity (Table 2).

Table 2.

Outcome parameters at 1 and 2 years after baseline depend on NSAID index >50 or NSAID index <50

Conclusions Long reception of NSAIDs in patients with early axSpA reduces disease activity, however, the receive frequency does not affect the activity of the disease.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.